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ABSTRACT
The enzymes catalysing the modification of the wobble uridine (U34) of tRNAs (U34-enzymes) play an
important role in tumor development. We have recently demonstrated that the U34-enzymes are crucial
in the survival of glycolytic melanoma cultures through a codon-specific regulation of HIF1α mRNA
translation. Moreover, depletion of U34-enzymes resensitizes resistant melanoma to targeted therapy.
These results indicate that targeting U34-enzymes represents a new therapeutic opportunity for mela-
noma patients.
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Reprogramming of mRNA translation has recently emerged
as a central mechanism driving the adaptation of tumor cells
during cancer progression and response to therapy.1 mRNA
translation is based on the pairing between codons of mRNAs
and anticodons of tRNAs. Modifications of tRNA molecules
in the anticodon, and particularly at the wobble position,
directly impact their decoding capacity and affect translation
elongation.2 We previously showed that enzymes modifying
the tRNA wobble uridine (U34-enzymes) are essential during
WNT-driven intestinal cancer initiation,3 they promote breast
cancer metastasis,4 but they are dispensable for normal intest-
inal and breast tissue maintenance.3-5 In the current study,6
we explored whether wobble uridine tRNA modification con-
tributes to specific mRNA translation rewiring during onco-
gene-induced transformation and/or adaptation of cancer
cells to therapy.
Malignant melanoma is a highly aggressive form of skin
cancer whose incidence is rising worldwide and with poor
prognosis when not restricted by surgical exportation.
Genomics studies of human melanoma have shown that the
mitogen-activated protein kinase (MAPK) pathway is often
deregulated in melanoma, with nearly 50% of the patients
harbouring a single activating mutation of the BRAF gene,
with V600E being the most common mutation (BRAFV600E).
Specific inhibitors of the oncoprotein BRAFV600E have been
used in the clinic and despite dramatic anti-tumor responses
observed in the first weeks, insurgence of resistance deeply
limits their efficacy.7 Among the various resistance mechan-
isms already described, metabolic reprogramming towards
glycolysis has been shown to promote resistance towards
BRAF inhibitors in melanoma patients.8
In our recent study,6 we found that U34-enzymes are lar-
gely increased in human melanoma biopsies and primary
melanoma lines compared to healthy melanocytes. Genetic
deletion of elp3 (Elongator complex protein 3), one of the
key U34-enzyme, strongly impaired melanoma insurgence in
zebrafish with a BRAFV600E/p53−/- background. Moreover,
depletion of the U34-enzymes ELP3 or CTU1/2 (Cytoplasmic
tRNA 2-thiolation protein 1 and 2) induced cell death in
patient-derived BRAFV600E melanoma cultures. By combining
comparative proteomics and metabolomics approaches, we
demonstrated that highly glycolytic melanoma cultures are
dependent on U34-enzymes for survival. Specifically, we
showed that the mRNA translation of the transcription factor
Hypoxia-inducible factor 1-alpha (HIF1α), a key regulator of
glycolysis in the cells, is supported by the U34-enzymes. In
fact, depletion of U34-enzymes resulted in decreased amount
of HIF1α protein levels due to abnormal accumulation of the
ribosomes and defective translation elongation at the HIF1α
transcript. Strikingly, we found that this effect is codon-spe-
cific, as a systematic replacement of the U34-sensitive codons
(namely AAA, GAA and CAA) in HIF1α mRNA into their
insensitive synonymous counterpart (respectively AAG, GAG
and CAG), abolished the need of U34-enzymes during HIF1α
translation: it normalized ribosome distribution along HIF1α
transcript and it restored HIF1α protein expression upon
depletion of U34-enzymes. This indicates that U34-enzymes
regulate HIF1α translation in a codon-specific manner
(Figure 1).
Previous studies have associated HIF1α expression and
glycolytic switch to insurgence of resistance towards MAPK-
based targeted therapies in melanoma.9 We found that resis-
tant and metastatic malignant melanoma have higher levels of
the U34-enzymes and of HIF1α. Strikingly, when we depleted
the U34-enzymes in both in vitro and in vivo models of
resistant melanoma, tumors were resensitized to targeted
therapy. Moreover, this effect is, at least in part, due to
HIF1α mistranslation. These results indicate that U34-
enzymes promote resistance towards targeted therapy, at
least by promoting codon-specific HIF1α mRNA translation.
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Resistance in melanoma is often mediated by activation of the
Phosphoinositide-3-Kinase (PI3K) pathway.7 In our study, we
highlighted that the PI3K-mTOR Complex 2 (mTORC2) axis
directly regulates the U34-enzymes through phosphorylation
and stabilization of the scaffold Elongator protein 1 (ELP1),
suggesting that the levels of U34-enzymes are dynamically
regulated in time by the oncogenic PI3K-mTORC2 pathway,6
(Figure 1).
The efficacy of targeted therapies in melanoma is strongly
limited by the insurgence of resistance, which causes relapses.
In our study, we uncovered a novel resistance mechanism
through upregulation of wobble uridine tRNA modification
and codon-specific reprogramming of mRNA translation. We
highlighted a new family of enzymes that is essential to
promote adaptation to therapy and acquisition of resistance
by regulation of selective mRNA translation.6 These data are
highly significant for the patients because they suggest that
targeting the U34-enzymes in combination with MAPK-based
therapies might become a new therapeutic option to prolong
treatment efficacy and to prevent tumor relapse.
Further questions remain. First, although we have shown
that HIF1α, whose mRNA is enriched in U34-codons, relies on
U34-enzymes for its expression, it is still unclear how ribo-
some pausing at specific codons in mRNAs affects subsequent
protein expression. One possible explanation is that a slow-
down during translation elongation, as seen upon U34-
enzymes depletion, affects co-translational protein folding.
This is supported by our data showing that the newly synthe-
tized HIF1α is directed to the protein aggregates upon deple-
tion of U34-enzymes. Being able to predict the proteome that
relies on U34-enzymes for correct expression is essential to
identify the pathological contexts where the U34-enzymes play
key roles. Second, we demonstrated that the PI3K-mTORC2
signalling pathway regulates the levels of the U34-enzymatic
complex Elongator. Understanding the precise mechanisms
underlying this regulation merits further investigation. In
which cellular compartment does this happen? What other
pathway(s) could be involved? How does this regulation
translate into U34-tRNA modifications and how does it
impact on mRNA translation and the establishment of a
specific proteome? Investigating how U34-enzymes are regu-
lated is crucial to predict their real impact in normal physiol-
ogy and in pathophysiological conditions.
Modifications of tRNAs and their role in the regulation of
specific translational reprogramming is a new and exciting
field which has rapidly expanded in the last years. Our find-
ings bring a new important piece of evidence demonstrating
the role of U34-enzymes in cancer adaptation to therapy by
sustaining metabolic rewiring through codon-dependent reg-
ulation of HIF1α mRNA translation. Given the importance of
HIF1α transcriptional activity in various malignant tumors,10
the targeting the U34-enzymes might prove to be relevant not
only for melanoma patients but also in a wide range of
cancers.
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Figure 1. Mechanisms linking U34-enzymes to melanoma cell survival and resistance to targeted therapy. Wobble uridine tRNA modifying enzymes (U34-enzymes)
are upregulated in malignant melanoma following activation of the Phosphoinositide-3-Kinase (PI3K) signalling pathway through a direct, mTOR Complex 2
(mTORC2)-dependent mechanism. U34-enzymes promote mRNA translation of Hypoxia-induced factor 1-alpha (HIF1α) in a codon-dependent manner to sustain high
levels of HIF1α and maintain a glycolytic metabolism, which confers resistance toward MAPK-based therapy.
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